BRIAN B. HANSEN - 15 May 2023 Form 4 Insider Report for TANDEM DIABETES CARE INC (TNDM)

Role: EVP & CHIEF COMMERCIAL OFFICER
Signature: /s/ Rachel Malina, Attorney-in-Fact for Brian B. Hansen
Issuer symbol: TNDM
Transactions as of: 15 May 2023
Net transactions value: -$4,642
Form type: 4
Filing time: 17 May 2023, 18:15:00 UTC
Previous filing: 01 Mar 2023
Next filing: 30 May 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TNDM	Common Stock	Award	$17,239	+631	+7.1%	$27.32	9,578	15 May 2023	Direct	F1
transaction	TNDM	Common Stock	Options Exercise	$0	+163	+1.7%	$0.000000	9,741	15 May 2023	Direct
transaction	TNDM	Common Stock	Tax liability	$1,735	-54	-0.55%	$32.13	9,687	15 May 2023	Direct	F2
transaction	TNDM	Common Stock	Options Exercise	$0	+1,897	+20%	$0.000000	11,584	15 May 2023	Direct
transaction	TNDM	Common Stock	Tax liability	$20,146	-627	-5.4%	$32.13	10,957	15 May 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TNDM	Restricted Stock Unit	Options Exercise	$0	-163	-11%	$0.000000	1,299	15 May 2023	Common Stock	163		Direct	F3, F4
transaction	TNDM	Restricted Stock Unit	Options Exercise	$0	-1,897	-33%	$0.000000	3,794	15 May 2023	Common Stock	1,897		Direct	F3, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reporting person is voluntarily reporting the acquisition of shares of common stock pursuant to the Tandem Diabetes Care, Inc. Amended and Restated 2013 Employee Stock Purchase Plan (ESPP), for the ESPP purchase period of November 16, 2022 through May 15, 2023. This transaction is also exempt under Rule 16b-3(c).
F2	Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.
F3	Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan (the 2013 Plan).
F4	RSU granted on 5/18/2021 vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on the 15th day of the month that corresponds to the anniversary of the grant date, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter, subject to the terms of the 2013 Plan.
F5	RSU granted on 5/25/2022 vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on the 15th day of the month that corresponds to the anniversary of the grant date, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter, subject to the terms of the 2013 Plan.